Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]

Aydan Eroǧlu; A. Ulu; R. Çam; N. Akar

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]

Aydan Eroǧlu, A. Ulu, R. Çam, N. Akar

Research output: Contribution to journal › Article › peer-review

Abstract

In summary, we found that PAI-1 4G/5G polymorphism is associated with the risk of malignant tumor development and we suggest that this polymorphism may contribute to an inherited predisposition to the development of malignancies; however further studies with larger series from diverse ethnic populations are needed to confirm our results.

Original language	English (US)
Pages (from-to)	135-136
Number of pages	2
Journal	Journal of B.U.ON.
Volume	12
Issue number	1
State	Published - Jan 2007
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]'. Together they form a unique fingerprint.

Cite this

@article{bebd6b666b4d4d8c835c39005e44d245,

title = "Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]",

abstract = "In summary, we found that PAI-1 4G/5G polymorphism is associated with the risk of malignant tumor development and we suggest that this polymorphism may contribute to an inherited predisposition to the development of malignancies; however further studies with larger series from diverse ethnic populations are needed to confirm our results.",

author = "Aydan Eroǧlu and A. Ulu and R. {\c C}am and N. Akar",

year = "2007",

month = jan,

language = "English (US)",

volume = "12",

pages = "135--136",

journal = "Journal of B.U.ON.",

issn = "1107-0625",

publisher = "Balkan Union of Oncology",

number = "1",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]

AU - Eroǧlu, Aydan

AU - Ulu, A.

AU - Çam, R.

AU - Akar, N.

PY - 2007/1

Y1 - 2007/1

N2 - In summary, we found that PAI-1 4G/5G polymorphism is associated with the risk of malignant tumor development and we suggest that this polymorphism may contribute to an inherited predisposition to the development of malignancies; however further studies with larger series from diverse ethnic populations are needed to confirm our results.

AB - In summary, we found that PAI-1 4G/5G polymorphism is associated with the risk of malignant tumor development and we suggest that this polymorphism may contribute to an inherited predisposition to the development of malignancies; however further studies with larger series from diverse ethnic populations are needed to confirm our results.

UR - http://www.scopus.com/inward/record.url?scp=34249731935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249731935&partnerID=8YFLogxK

M3 - Article

C2 - 17436417

AN - SCOPUS:34249731935

VL - 12

SP - 135

EP - 136

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 1

ER -

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients [2]

Abstract

ASJC Scopus subject areas

Other files and links

Cite this